Myasthenia Gravis Treatment Market to Reach $5.9 Billion by 2035

Myasthenia gravis treatment market was valued at $2.2 billion in 2025 and is projected to reach $5.9 billion by 2035, expanding at a CAGR of 10.6% during 2026–2035. The increasing prevalence of autoimmune disorders and the growing emphasis on early diagnosis and targeted biologic therapies are significantly driving demand across the market. Governments and healthcare systems globally are strengthening rare disease frameworks and expanding access to advanced immunotherapies, which is accelerating treatment adoption rates. Rising awareness, improved diagnostic capabilities, and enhanced reimbursement frameworks are contributing to higher treatment penetration. Pharmacological therapies continue to dominate the market, while rapid immunotherapies and biologics are witnessing accelerated uptake due to their effectiveness in managing moderate to severe cases. Hospitals and specialty neurology clinics remain the primary treatment centers, supported by expanding home care settings for long-term disease management.

Browse the full report description of “Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report, By Treatment Modality (Pharmacological Therapies, Rapid Immunotherapies, Surgical Treatment), By Route of Administration (Oral, Intravenous (IV), Subcutaneous (SC)), By End User (Hospitals, Specialty Neurology Clinics, Ambulatory Surgical Centers, Homecare Settings, Others), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/myasthenia-gravis-treatment-market

The increasing global burden of autoimmune diseases is a major macro driver fueling growth in the myasthenia gravis treatment market. According to data published by the World Health Organization (WHO) and national health agencies, autoimmune diseases affect approximately 8–10% of the global population, with incidence rates steadily rising due to environmental and genetic factors. In the United States, the National Institutes of Health (NIH) estimates that autoimmune diseases collectively impact over 24 million individuals, with additional millions remaining undiagnosed. Myasthenia gravis, although classified as a rare disease, has shown increasing prevalence due to improved detection and aging populations. Government-backed rare disease initiatives between 2023 and 2026 have significantly enhanced patient identification and access to treatment. For instance, the U.S. Food and Drug Administration (FDA) expanded orphan drug designations and accelerated approval pathways for novel biologics targeting neuromuscular disorders during this period. Similarly, the European Medicines Agency (EMA) strengthened its rare disease strategy under the EU4Health program, supporting faster approvals and broader patient access. These regulatory and policy-level interventions are directly contributing to increased adoption of advanced therapies, particularly monoclonal antibodies and complement inhibitors, thereby driving sustained market growth.

The market is witnessing a strong shift toward targeted biologic therapies and rapid immunotherapies, which offer improved efficacy and reduced side effects compared to traditional treatments. Intravenous (IV) and subcutaneous (SC) administration routes are gaining traction, especially for biologics and immunoglobulin therapies, enhancing patient convenience and compliance. Pharmacological therapies, including acetylcholinesterase inhibitors and corticosteroids, continue to serve as first-line treatments. However, rapid immunotherapies such as intravenous immunoglobulin (IVIG) and plasma exchange are increasingly used in acute exacerbations. Surgical interventions, particularly thymectomy, remain a critical option for specific patient populations. The growing integration of personalized medicine and biomarker-driven treatment approaches is further transforming the therapeutic landscape, enabling more precise and effective disease management.

Innovation Leaders Transforming the Myasthenia Gravis Treatment Market

The key players operating in the myasthenia gravis treatment market include UCB S.A., AstraZeneca (Alexion Pharmaceuticals), Takeda Pharmaceutical Company, Argenx SE, and CSL Limited (CSL Behring), among others. These companies are actively investing in advanced biologics, monoclonal antibodies, and immunotherapies to address unmet clinical needs and improve patient outcomes.

• In January 2026, Argenx recently advanced its position in the myasthenia gravis treatment market with the FDA’s acceptance and priority review of its supplemental biologics license application for VYVGART targeting AChR-antibody seronegative generalized myasthenia gravis. Supported by strong Phase 3 data demonstrating significant clinical improvement, this development aims to expand treatment access to underserved patient subgroups.

• In June 2024, Takeda Pharmaceutical Company strengthened its position in the myasthenia gravis treatment market through a $230 million investment to expand plasma-derived therapy production capacity in Los Angeles. This expansion enhances supply reliability for immunological and rare disease treatments, including therapies relevant to autoimmune conditions like Myasthenia Gravis. The initiative also integrates advanced manufacturing and digital technologies, improving efficiency and scalability.

These strategic developments highlight the increasing focus on innovation, pipeline expansion, and global market penetration, which are expected to significantly drive competition and growth in the coming years.

Market Coverage

• Market size available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segments Covered –
• By Treatment Modality
• By Route of Administration
• By End User

Competitive Landscape – UCB S.A., AstraZeneca (Alexion Pharmaceuticals), Takeda Pharmaceutical Company, Argenx SE, CSL Limited (CSL Behring), among others

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who are the leading players in the market?
• How are companies addressing challenges to sustain growth?
• Where are the key investment opportunities?

Global Myasthenia Gravis Treatment Market Segment

By Treatment Modality

• Pharmacological Therapies
• Rapid Immunotherapies
• Surgical Treatment

By Route of Administration

• Oral
• Intravenous (IV)
• Subcutaneous (SC)

By End User

• Hospitals
• Specialty Neurology Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Others

Global Myasthenia Gravis Treatment Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/myasthenia-gravis-treatment-market